Air microbubbles have been investigated recently at high magneticˆeld strength (2 Tesla or greater) as potential MR susceptibility contrast agents. We used a phantom to measure their susceptibility at 1.5T to clarify their usefulness for this purpose. The phantom,ˆlled with fresh Levovist } suspension at 4 diŠerent doses (67 to 125 mg W mL), was continuously scanned with a gradient-echo technique at a temporal resolution of 10 s. The transverse relaxation increase (R 2 *) by microbubbles demonstrated a time course of exponential decay at each dose (time-constant, 39 to 57 s). The dependency of R 2 * on microbubble volume fraction was linear, with a slope of 89 s -1 per percentage microbubble volume fraction. Our study represents theˆrst step towards applying microbubbles as susceptibility contrast agents at 1.5T.
Introduction
Gas-ˆlled microbubbles, originally developed as ultrasound contrast agents to enhance backscattering contrast, 1, 2 have recently been investigated for use in magnetic resonance (MR) imaging. [3] [4] [5] [6] [7] If the susceptibility of the gas diŠers from that of the surrounding medium, microbubbles create localized perturbations in the magneticˆeld, thereby acting as``susceptibility contrast agents'' and shortening T2 and T2*. The eŠects depend on magneticˆeld strength and are much greater at higherˆeld strength. 7, 8 An early experiment with Albunex } microbubbles on a 2T MR scanner showed the potential of air-ˆlled microbubbles as MR susceptibility contrast agents. 3 Another experimental study on a 4.7T MR scanner explored the potential application of microbubbles as MR pressure sensors based on pressure-induced susceptibility change, 5 and recently, an animal study of Optison } microbubbles at 7T demonstrated their potential application as MR intravascular susceptibility contrast agents in vivo. 6 Microbubbles used in these studies were coated with shells of liposomes or human albumin to improve their stability.
The above studies provided various important information about gas-ˆlled microbubbles. However, all studies were performed with high-ˆeld MR systems because microbubbles have a relatively weaker susceptibility eŠect than other intravascular susceptibility contrast agents. 9, 10 Because a magneticˆeld strength of 1.5T is more common than 2T or greater for clinical purposes, an important and fundamental issue to be discussed next would be whether air microbubbles could be susceptibility contrast agents at 1.5T. Although their weak susceptibility contrast might be expected at 1.5T from theoretical considerations, no experimental study has been reported. Our purpose was to evaluate the susceptibility eŠect of air microbubbles at 1.5T using a phantom.
Materials and Methods
We used the ultrasound contrast agent, Levovist } (Schering AG, Berlin, Germany), which is composed of galactose (99.9z) and palmitic acid (0.1z). When mixed with water, Levovist } produces microbubbles of air (mean diameter＝3 mm) covered by a thin stabilizing layer of palmitic acid. 2 We prepared the Levovist } according to the instructions of the manufacturer and obtained a microbubble suspension with a concentration of 200 mg W mL of Levovist } (2.5 g of Levovist } in 12.5 mL of water, approximately 4×10 7 bubbles W mL) after 2 min of equilibration.
Phantom study was performed on a 1.5T wholebody scanner (Signa Horizon LX, GE Medical Systems, Milwaukee, Wisconsin) with a standard quadrature head coil. A 12.5-mL syringe (attached to the water-ˆlled rectangular bottle) was placed vertically inside the head coil. The syringe phantom was connected with a tube 2 meters long and 3.8 mL in volume and in line with a Y-adapter leading to 2 syringes (one for the Levovist } suspension, one for water) outside the magnet. The susceptibility eŠect of air microbubbles in 4 diŠerent doses was measured using fresh Levovist } suspensions. At the beginning of each measurement, automatic shimming and preparation scan were performed with the syringe phantomˆlled with 12.5 mL water. On completion of the preparation scan, 40 serial gradient-echo images were acquired with a temporal resolution of one frame per 10 s. The imaging parameters were repetition time (TR)＝ 100 ms; echo time (TE)＝60 ms; ‰ip angle＝109 ; number of excitations (NEX)＝1; rectangularˆeld of view＝20×10 cm 2 with matrix of 128×96; and slice thickness＝10 mm. The vertical scan section was positioned through the center of the syringe phantom. Just after continuous scan was started, water was partially drained from the phantom and the Levovist } suspension was slowly introduced into the phantom to avoid possible microbubble destruction from high pressure. Because the tube had a 3.8-mL dead volume, a 3.8-mL water ‰ush was administered immediately thereafter to drive the microbubble suspension from the tube into the phantom. This reˆlling process was completed within 20 s. Four diŠerent doses (125, 100, 76, and 67 mg W mL) of diluted suspension (total volume＝ 12.5 mL) were achieved by replacing a certain amount of water in the syringe phantom with the Levovist } suspension. During the reˆlling process, the syringe supplying the suspension was constantly stirred by hand to ensure uniform suspension of microbubbles. Finally, similar measurement was conducted using water instead of the Levovist } suspension to obtain baseline signal changes by saturation eŠect from continuous acquisition. Serial images acquired after the reˆlling process were used for further analysis.
The time course of signal intensity in the syringe phantom was measured by placing a constant region of interest (ROI), which almost covered the area with ‰uid (suspension or water) in the phantom, on each image. To avoid unfavorable eŠects from turbulent ‰ow caused by the reˆlling process, theˆrst image in each measurement, which corresponded to initial 10-s signal behavior, was excluded. The signal intensity at time t with microbubble administration, S(t), was compensated by dividing it by the signal intensity at time t with water administration, where time t was realigned to the start of the acquisition for second image as t＝0 s.
The susceptibility of air microbubbles was measured by transverse relaxation increase (R2 * ). The time course of the transverse relaxation increase R2*(t) was estimated as:
where Sf is theˆnal signal intensity (averaged at last 3 time points). From theoretical and experimental studies of microbubble susceptibility, R2* is known to be proportional to the microbubble volume fraction.
5-7

Results
The susceptibility of air microbubbles at 4 diŠer-ent doses at 1.5T was observed as transverse relaxation increase. The time course R2*(t) demonstrated monoexponential decay at each dose (Fig. 1) . Time constants of the decay obtained from monoexponentialˆts were 39 s for 125 mg W mL; 50 for 100 mg W mL; 51 for 76 mg W mL; and 57 for 67 mg W mL. Because R2 * was considered to be proportional to the microbubble volume fraction, [5] [6] [7] the microbubble concentration was exponentially decreased over time in the syringe phantom. Figure 2 shows the 
Discussion
To our knowledge, no study has evaluated the susceptibility eŠect of air microbubbles at 1.5T, even though its presence is expected theoretically. 7 A major reason is the weak diŠerence in susceptibility between air and its surrounding medium. For a given microbubble concentration, R2 * is known to be quadratic or linear (depending on the analyticalˆeld distribution form 7, [11] [12] [13] ) to the magnetiĉ eld strength. 7, 11, 14 This implies that a high magneticˆeld is necessary to measure such weak susceptibility. Thus, previous studies 3, 5, 6 could be conducted at advantageous high magneticˆelds (2T or greater). Although the availability of high-ˆeld MR systems has increased, in most hospitals, magnetiĉ elds of MR scanners do not exceed 3T. Hence, if the microbubble susceptibility eŠect is measurable at 1.5T, microbubbles may be a viable, less toxic, and unique contrast agent. In this preliminary study, we measured the susceptibility eŠect of microbubbles at 1.5T using a phantom.
In the phantom study with Levovist } microbubbles, there were several obstacles to accurately measuring susceptibility. First, microbubbles disappear over time, perhaps by their upward migration caused by the buoyant force as well as their decay. Second, because Levovist } microbubbles are shorter lived than other ultrasound contrast agents 2 and their low stability enhances decay, preparation of a phantom should be completed during a brief period prior to MR measurement. Finally, for the same reason, su‹cient temporal and spatial resolution is required to detect slight changes in MR signal. Taking these circumstances into account, our phantom was designed to beˆlled with fresh microbubble suspension during MR measurement. Standard gradient-echo rather than echo-planar imaging was used to avoid the image distortion that aŠects detection of slight changes in signal.
Microbubble susceptibility was observed as transverse relaxation increase in the 4 doses studied. The time course of R2* showed exponential decay with a short time-constant, indicating that Levovist } microbubbles migrated upward or were destroyed quickly. This exponential decay is consistent with the signal behavior reported in an ultrasound experimental study with Levovist } . 2 There was close correlation between R2* and the estimated microbubble volume fraction obtained from data with 4 doses at 4 initial phases, even though it was di‹cult to accurately control microbubble concentration. Although this linear relationship implies their potential as susceptibility contrast agents at 1.5T, the weakness in susceptibility eŠect is still a limitation.
One way to increase the susceptibility eŠect without increasing magneticˆeld strength is to increase the radius of microbubbles because R2* increases signiˆcantly with the radius when the radius is in the mm range. 7, 11, 13, 15 It should be noted that microbubbles whose radius is beyond the range will not further increase R2 * because the R2 * remains constant beyond a critical radius and microbubbles will beˆltered by the lung capillary bed if they are intravenously administered. Another method to improve susceptibility is to increase the microbubble concentration within the limitations from microbubble toxicity in vivo. [5] [6] [7] 13 Withˆrst-pass bolus delivery, a lower dose would achieve higher microbubble concentration. Microbubble susceptibility can also be enhanced by choice of gas. 5, 7 For example, because oxygen is paramagnetic, it may enable greater susceptibility than would air (21z oxygen by volume). Improved stability of microbubbles is also essential in sustaining microbubble concentration at a higher level for a longer period and is accomplished by coating the microbubbles with shells. In conjunction with this, an ultimate solution to increase susceptibility can be achieved by compounding in the shells agents that have large magnetic dipolar moments, such as gadolinium or iron oxide. Though this method is expected to enhance microbubble toxicity, coating with gadolinium chelate, such as gadolinium-DTPA (diethylenetriaminepentaacetic acid), that would be nontoxic at low doses can safely produce the desired eŠect. 7 Our study has several major limitations. First, as mentioned, the technical di‹culties of handling short-lived microbubbles could aŠect accurate and precise measurement of R2*. Second, unfavorable eŠects from turbulent ‰ow caused by phantom preparation could not be eliminated completely even though theˆrst image corresponding to the initial 10-s signal behavior was excluded from analysis. Finally, and most importantly, no in vivo study directly demonstrating the potential application of microbubbles as a susceptibility agent at 1.5T was performed. Further studies including in vivo assessment of susceptibility eŠect by air microbubbles as well as their optimization for MR imaging are necessary.
In summary, MR susceptibility from air microbubbles was detectable as an increase of R2* at 1.5T. This preliminary study suggests that air microbubbles may be useful MR susceptibility contrast agents at 1.5T.
